Subscribe
Share
Share
Embed
Abbott separates its $8.5B nutrition arm including Ensure and Pedialyte; a two-year trial finds fish oil fails on brain health; GLP-1 supplements face regulatory heat; Cymbiotika enters beauty.
Abbott is freeing its $8.5B nutrition division — including Ensure and Pedialyte — as a standalone public company. And a landmark clinical trial just dealt a serious blow to fish oil's brain health positioning.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Today's show is packed — we're covering one of the biggest structural shakeups the nutrition industry has seen in years.
Klara: We're also diving into a major clinical trial that throws cold water on fish oil and brain health.
Marco: Then — the GLP-1 supplement boom is drawing regulatory heat.
Klara: And Cymbiotika is making its move into beauty supplements.
Marco: Let's get into it.
Marco: Abbott is spinning its nutrition business out into a fully independent, publicly traded company.
Marco: Abbott is a massive American health conglomerate — medical devices, diagnostics, pharmaceuticals, and nutrition all under one roof. The nutrition arm has always been a strong performer, but it's had to compete internally for capital and strategic attention alongside heart monitors and blood testing equipment. That's a real constraint for a business trying to move fast in a category as dynamic as functional nutrition.
Marco: The numbers here are significant. Abbott's nutrition division generates around eight and a half billion dollars in annual sales. That's not a niche supplements brand — that's a major global player. Brands like Ensure, the adult nutritional drink, and Pedialyte, the electrolyte rehydration range, will now sit inside a standalone business with its own board, its own investment priorities, and its own commercial ambitions.
Marco: From where I stand, this is genuinely exciting for the category. A business this size, freed from the priorities of a medical device parent, can move much faster. Expect accelerated product development, bolder marketing investment, and probably a more aggressive push into pharmacy, grocery, and specialist retail channels across Europe.
Klara: I'd look at this more cautiously. Ensure and Pedialyte are built on clinical credibility. That credibility comes partly from sitting inside a medically respected parent company. Once you're an independent nutrition business, you're competing in a noisier market. You need EFSA-authorised health claims — that's the EU's formal approval process for what you're allowed to say on pack — to hold that positioning. Independence doesn't automatically deliver that.
Marco: That's a real tension worth watching as this spin-off takes shape.
Marco: Now, let's move to our next story.
Klara: A major two-year clinical trial has found that fish oil supplements do not improve memory or protect cognitive function — even when they successfully raise omega-3 levels in the brain.
Klara: Fish oil is one of the biggest-selling supplement categories in Europe and globally. Brain health is central to how it's marketed — you'll see it on packaging in every pharmacy and health retailer you walk into. Consumers are spending real money based on that promise.
Klara: Here's what the study found. Participants took fish oil supplements for two years. Researchers confirmed that omega-3 fatty acids did reach the brain — levels genuinely increased. But despite that measurable uptake, participants showed no improvement in memory or cognitive protection compared to those who took nothing. The delivery worked. The outcome didn't follow.
Klara: From a regulatory standpoint, this matters enormously. EFSA — the EU's food safety authority — already sets a very high bar for brain health claims. This study adds weight to that caution. Brands marketing fish oil on a cognitive platform should be reviewing their claims carefully right now.
Marco: Commercially, this is uncomfortable but not catastrophic. Fish oil still has solid, well-established support for cardiovascular health — that's a credible pivot point for marketers. Smart brands will tighten their messaging and move toward endpoints where the evidence actually holds up.
Klara: I'd be more direct about it. Pivoting the message doesn't fix the underlying problem. If the cognitive claim was the reason millions of consumers were buying the product, that's a trust issue, not just a messaging exercise.
Marco: That's a fair challenge for the whole category to sit with.
Klara: Now, on to our next story.
Marco: GLP-1 weight-loss drug users are increasingly stacking dietary supplements alongside their medication — and doctors and regulators are starting to take notice.
Marco: GLP-1 drugs — think Ozempic and Wegovy — have reshaped the weight management market. Millions of Europeans are now using them. That's created a huge adjacent opportunity for supplement brands positioning their products as companions to the GLP-1 journey. Muscle support, nutrient replenishment, appetite management — the category exploded almost overnight.
Marco: Now the pushback is arriving. Doctors are raising concerns that supplement claims targeting GLP-1 users often lack clinical backing specific to that population. Regulators in multiple markets are actively exploring new rules to address the trend. No final framework has been announced yet, but the direction of travel is clear — this space is being watched, and the tolerance for vague or unsupported claims is shrinking.
Klara: From a regulatory standpoint, this was predictable. Under EU health claims regulation — the rules that govern what you can say on pack — you need authorised claims backed by solid evidence. A claim like "supports your GLP-1 journey" has no authorised basis whatsoever. Brands have been operating in a grey area, and that area is narrowing fast.
Marco: Commercially, I'd frame this as a deadline rather than a disaster. The demand from GLP-1 users is real and durable — these are people with genuine nutritional needs. Brands that invest in proper clinical substantiation now will own a defensible position when the rules tighten. Those who don't will lose shelf space when regulators move.
Klara: The problem is that clinical studies take time. Brands who chased this trend with weak claims and no research pipeline don't have an easy escape route.
Marco: Let's move to our final story of today.
Klara: Cymbiotika — a supplement brand built around liposomal delivery technology — is now moving into the beauty supplement space.
Klara: Liposomal delivery means wrapping active ingredients in tiny fat-based particles to help the body absorb them more effectively. It's a real and well-researched format, and it's been Cymbiotika's core identity since the brand launched. That's a meaningful technical foundation — not marketing window dressing.
Klara: The numbers are notable. The brand has sold 200 million liposomal sachets, which places it firmly in the premium supplement tier. Now it's turning that delivery credibility toward ingestible beauty — think skin, hair, and nail supplements taken orally rather than applied topically.
Klara: From a science standpoint, the bioavailability argument is more interesting here than in most beauty supplement launches. The ingestible beauty category is full of products where the active ingredients are poorly absorbed — the dose sounds impressive on pack but doesn't translate inside the body. If Cymbiotika can demonstrate that their liposomal format genuinely improves uptake of beauty-relevant ingredients like collagen peptides or ceramides, that's a substantive claim. But the operative word is demonstrate. EFSA's bar for beauty-linked health claims is high, and a delivery format story alone doesn't unlock authorised claim territory in Europe.
Marco: Commercially, this is a smart move. The ingestible beauty market in Europe is growing fast — you can see it across pharmacy counters, in dm and Boots, and in the premium skincare adjacencies on Amazon. Cymbiotika is entering with built-in brand equity and a differentiated story. That's a strong starting position.
Klara: I'd push back slightly on that. A differentiated story and a clinically substantiated story are two different things. Beauty supplement shoppers are becoming more sceptical — they've seen too many collagen drinks that didn't deliver. Efficacy credentials need to be real, not just well-packaged. That's the bar Cymbiotika now has to clear.
Marco: The brands that survive the next round of consolidation in this category will be those that invested in the science, not just the sachet design.
Marco: Today's stories share one thread — proof matters more than positioning now, whether you're spinning out an $8.5 billion division or launching a beauty sachet.
Klara: And if your product can't survive a two-year clinical trial or a regulatory spotlight, no delivery technology or GLP-1 halo will save it.